AU Patent

AU2018373675B2 — A double-labeled probe for molecular imaging and use thereof

Assigned to Deutsches Krebsforschungszentrum DKFZ · Expires 2022-06-16 · 4y expired

What this patent protects

The present invention relates to a compound or a pharmaceutically acceptable salt thereof of formula (I) wherein (A) is at least one motif specifically binding to cell membranes of neoplastic cells; (B) at least one chelator moiety of radiometals; (C) a dye moiety; x

USPTO Abstract

The present invention relates to a compound or a pharmaceutically acceptable salt thereof of formula (I) wherein (A) is at least one motif specifically binding to cell membranes of neoplastic cells; (B) at least one chelator moiety of radiometals; (C) a dye moiety; x

Drugs covered by this patent

lutetium-lu-177-vipivotide-tetraxetan (LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN)

Patent Metadata

Patent number: AU2018373675B2
Jurisdiction: AU
Classification: —
Expires: 2022-06-16
Drug substance claim: No
Drug product claim: No
Assignee: Deutsches Krebsforschungszentrum DKFZ
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.